Core Viewpoint - Zhejiang Tailin Biotechnology Co., Ltd. has recently obtained five patent certificates, which will enhance its intellectual property protection and maintain its technological leadership in the industry [4]. Patent Acquisition Summary - The company’s wholly-owned subsidiary, Zhejiang Tailin Life Science Co., Ltd., has acquired five patents, including one invention patent. The details are as follows: - Patent for gas sterilization resistance detection device and method (Invention) [4] - Appearance patents for two types of plankton pretreatment equipment, a stationary sampler, and a compressed air microbiological testing instrument [4]. - The patents are expected to strengthen the company's innovation mechanism and core competitiveness, although they will not have a significant immediate impact on production and operations [4].

Group 1 - TaiLin Bio (SZ 300813) announced on September 22 that its wholly-owned subsidiary, Zhejiang TaiLin Life Sciences Co., Ltd., has recently obtained 5 patent certificates [1] - The patents include "Gas Sterilization Resistance Detection Device and Method for Zero Rise Period of Gas Concentration" and "Plankton Pretreatment Equipment (1)" [1] - For the fiscal year 2024, TaiLin Bio's revenue composition is projected to be 90.04% from the pharmaceutical industry and 9.96% from other businesses [1] Group 2 - As of the report, TaiLin Bio has a market capitalization of 4.5 billion yuan [1]

南财智讯9月22日电，泰林生物发布公告称，全资子公司泰林生命科学近日收到国家知识产权局颁发的5 项《专利证书》。专利名称分别为"气体浓度零上升期的气体灭菌抗力检测装置及其检测方法"、"浮游 生物预处理设备（1）"、"静置取样器"、"压缩空气微生物检验仪"和"浮游生物预处理设备（2）"。 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-074 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）于近期共取得了 5 项专利证书 （其中发明专利 1 项），具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 气体浓度零上升期的气体灭菌抗 力检测装置及其检测方法 | 发明 | 2023108605872 | 2025/9/12 | 泰林生命科学 | | 2 | 浮游生物预处理设备(1) | 外观 | 2024307565163 | 2025/9/12 | 泰林生命科学 | | 3 | 静置取样器 | 外观 | 2024307575339 | 2025/9/12 | 泰林生命科学 | | 4 | 压缩空气微生物检验仪 | 外观 | 2024307729182 | 2025/9/12 | 泰林生命科学 | | 5 | 浮游生物预处理设备(2) ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301013 | 利和兴 | 29.23 | 19.99% | 90.83万 | | 25.79亿 | | 300521 | 爱司凯 | 32.30 | 16.56% | 29.95万 | | · 9.47 C | | 688400 | 凌云光 | 50.02 | 12.46% | 45.85万 | | 22.31亿 | | 688630 | 心碁微装 | 156.00 | 7.59% | 13.25万 | | 20.35亿 | | 300499 | 高潮股份 | 34.51 | 6.97% | 93.39万 | | 31.15亿 | | 301260 | 格力博 | 23.00 | 5.31% | 25.75万 | | 5.98亿 | | 002031 | 巨轮智能 | 9.51 | 5.08% | 603.29万 | | 58.22亿 | | 001400 | 江顺科技 | 81.24 | 4.13% | 4.55万 | | 3 ...

Group 1 - The stock of Tailin Bio (300813.SZ) has decreased by 5.33%, currently trading at 38.18 yuan, with a transaction volume of 150 million yuan and a market capitalization of 4.63 billion yuan [1] - The stock reached a high of 42.25 yuan yesterday, marking a new high for approximately 33 months since December 23, 2022 [1] - Tailin Bio announced that from August 8 to September 17, 2025, its controlling shareholder and actual controller's concerted action party, Gao De Investment, will reduce its holdings by a total of 1.18177 million shares, accounting for 0.98% of the company's total share capital [1] Group 2 - Following this equity change, the shareholding ratio of the company's controlling shareholder, actual controller, and their concerted action parties will decrease from 58.91% to 57.94% [1]

本次权益变动后，公司控股股东、实际控制人及其一致行动人持股比例由58.91%下降至 57.94%。 9月17日，泰林生物(300813.SZ)发布公告称，2025年8月8日至2025年9月17日，公司控股股 东、实际控制人的一致行动人高得投资通过集中竞价方式合计减持118.177万股，占公司总股本比 例的0.98%。 ...

Policy Developments - The head of the National Medical Products Administration emphasized the importance of improving the efficiency of drug review and approval processes to ensure product quality and accelerate the market entry of new drugs [2] - Measures include prioritizing the review of urgently needed clinical products, reducing the review time for innovative drug clinical trials from 60 to 30 working days, and optimizing supplementary application review procedures [2] Industry Insights - The optimization of the review and approval process addresses the issues of "difficult and expensive medication" for patients, while also reducing time and institutional transaction costs for pharmaceutical companies, alleviating core pressures in R&D, production, and operations [3] Market Developments - Health 160 successfully listed on the Hong Kong Stock Exchange, closing at HKD 28.22 per share, with a market capitalization of HKD 9.495 billion [10] - Meikang Bio's subsidiary obtained a medical device registration certificate for four products, enhancing the company's product line and market competitiveness [7] Innovation and Drug Approvals - In the first seven months of the year, 50 innovative drugs were approved, surpassing the total of 48 for the entire previous year, indicating a strong momentum in drug innovation [13] - The approval of innovative drugs is driven by policy support, technological advancements, and increased capital investment, with a shift from me-too drugs to first-in-class innovations [13] Strategic Partnerships - Maiwei Bio signed an exclusive licensing agreement with Kalexo Bio, potentially receiving up to USD 1 billion in upfront and milestone payments, which is expected to positively impact the company's future performance [14]

Group 1 - On September 17, Junsheng Electronics disclosed an increase in shareholding, with Junsheng Group acquiring 700,000 A-shares during the period of unusual stock fluctuations [1][2] - A total of 29 A-share listed companies announced share reductions, including notable firms such as Shuanglu Pharmaceutical, Xinruida, and Boyun New Materials [1][2] Group 2 - Shuanglu Pharmaceutical's board secretary plans to reduce holdings by no more than 0.0365% of the company's shares [2] - Xinruida's shareholder Dai Yongjian intends to reduce holdings by no more than 0.13% [2] - Boyun New Materials' shareholder Gao Chuangtou plans to reduce holdings by no more than 1% [2] - Other companies with planned reductions include Guanggang Gas, Hanyi Co., and Weilan Lithium, with reductions ranging from 0.16% to 3.48% [2]

Group 1 - The company, Tailin Biological, responded to investor inquiries on September 17 regarding shareholder information, indicating that such details can be found in the company's periodic reports [2]